News
NETRF Scientific Advisor Dr. Daniel Halperin Takes on Pivotal Role at Winship Cancer Institute of Emory University
NETRF is pleased to announce that Daniel Halperin, MD, one of our distinguished Board of Scientific Advisors members, has been appointed Vice Chair of Clinical
Taking a Look at Proteins: Pioneering NETRF-Funded Research in Pancreatic Neuroendocrine Tumors
NETRF congratulates Dr. Michael Roehrl on his research progress and recent publication. NETRF’s recent Investigator Award to Michael Roehrl, MD, PhD, MBA, Chief of Pathology at…
Another CAR T-Cell Clinical Trial Open to Neuroendocrine Cancer Patients
A phase I CAR T-cell clinical trial targeting the molecule IL13Rα2 found on the surface of some tumors is being conducted at the University of
Honoring Leadership: Drs. Shivdasani, Fisher, and Chung Named BOSA Emeritus Members
The Neuroendocrine Tumor Research Foundation (NETRF) extends its deepest gratitude to Ramesh Shivdasani, MD, PhD (Dana-Farber Cancer Institute), George Fisher, MD, PhD (Stanford University), and Daniel Chung, MD (Massachusetts General Hospital) for their exceptional service as members and former Chairs of the NETRF Board of Scientific Advisors (BOSA).
Promising Advancement in Neuroendocrine Tumor Treatment: FDA Accepts Cabozantinib Application
The Neuroendocrine Tumor Research Foundation is excited to share an important update in the field of neuroendocrine tumor (NET) treatment. On August 6, 2024, Exelixis
Exploring New Research in Neuroendocrine Cancer Diagnosis and Treatment
Welcome to the latest research highlights from the Neuroendocrine Tumor Research Foundation (NETRF). In this blog post, we dive into two new research studies funded
Where Does Neuroendocrine Cancer Research Happen?
At the Neuroendocrine Tumor Research Foundation (NETRF), we are dedicated to funding groundbreaking research in neuroendocrine cancer, which includes neuroendocrine tumors (NETs) and neuroendocrine carcinomas
Thank You For Empowering Progress!
We did it! Thanks to our incredible NETRF community and the generous match from our board member Steve Kaufer, we raised over $115,000 for neuroendocrine
Driving Breakthroughs: Your Role in the 2024 NETRF Grant Cycle and Neuroendocrine Cancer Research
At NETRF, our dedication to advancing research is paramount because it holds the key to improving treatments and ultimately finding cures for neuroendocrine cancer. Research
New Clinical Trial Focuses on Use of Antibody-Drug Conjugate in Neuroendocrine Tumors and Carcinomas
A new first-in-human clinical trial at the National Institutes of Health in Bethesda, Maryland, is exploring the use of an antibody-drug conjugate (ADC), ADCT-701, in